RT Journal Article
SR Electronic
T1 Clinical health outcomes of Ebola virus disease survivors eight years post recovery: a cross-sectional study in Sierra Leone
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.29.24312780
DO 10.1101/2024.08.29.24312780
A1 Schindell, Brayden G.
A1 Titanji, Boghuma K.
A1 Rimoin, Anne W.
A1 Shaw, Souradet Y.
A1 Kangbai, Jia B.
A1 Kindrachuk, Jason
YR 2024
UL http://medrxiv.org/content/early/2024/08/29/2024.08.29.24312780.abstract
AB Background The West African Ebola virus disease (EVD) epidemic that occurred between 2013-2016 resulted in >28,000 confirmed cases and >11,000 fatalities. Thousands of survivors necessitate an understanding of the long-term health effects and future medical needs of these patients.Methods A cross-sectional study of 595 EVD survivors from Sierra Leone and 403 close contacts (n=998). An in-person survey conducted between November 2021 and March 2022 included demographics, clinical health symptomology assessment of each organ system and a reproductive health assessment including sexual dysfunction question sets. The frequency of each disorder was examined and the association of each disorder with EVD survival was assessed.Results Of 12 number of symptom types, five were reported by >50% of EVD survivors (Ocular, Neurological, Constitutional, Genitourinary, Dermatological), and all but one were reported by >40% of EVD survivors. Symptom types associated with EVD survival included ENT symptoms (AOR: 8.75, 95% CI: 5.63 – 13.60, p < 0.001), ocular symptoms (AOR: 7.18, 95% CI: 5.02 – 10.25, p < 0.001), dermatological symptoms (AOR: 4.16, 95% CI: 3.06 – 5.65, p < 0.001) and cardiovascular symptoms (AOR: 2.96, 95% CI: 2.12 – 4.13, p < 0.001).Conclusion The West Africa EVD epidemic resulted in a high prevalence of persistent health issues among disease survivors. Continued support for survivor services in West Africa is crucial, and future outbreak response planning should include dedicated funding to ensure adequate care for survivors, both during the acute phase of infection and throughout the post recovery period.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe would like to thank our funding sources JK is funded by a Tier 2 Canada Research Chair in the Molecular Pathogenesis of Emerging and Re-Emerging Viruses provided by the Canadian Institutes of Health Research (Grant no. 950-231498), and the Canadian Institutes of Health Research (Grant no. PJT-175098). BKT has received funding support from NIH Building Interdisciplinary Careers in Women’s Health (BIRCWH) Grant (K12HD085850) and from Emory’s Center AIDS Research Grant (P30 AI050409).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from the University of Manitoba Research Ethics Board [HS24515 (H2020:538)] and the Office of the Sierra Leone Ethics and Scientific Review Committee, Government of Sierra Leone.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDue to the sensitive nature of our survey and the involvement of human participants we did not receive approval to collect raw participant identified data from The University of Manitoba Research Ethics Board or the Sierra Leone Ethics and Scientific Review Committee. While participants additionally consented to the study with the knowledge that their data was collected in an anonymized manner with the only record of participants being record of payment only accessible by JK and JBK and securely stored in an encrypted file. Upon reasonable request however, the anonymized raw study data can be made available through the following persons 1) from UM REB by contacting the office (Email: bannreb{at}umanitoba.ca) 2) Edward Foday, Research and Publications Specialist, Sierra Leone Ethics and Scientific Review Committee, Directorate of Policy, Planning and Information, Ministry of Health and Sanitation, Fifth Floor, Youyi Building, East Wing, Freetown, Sierra Leone (Email: efoday{at}health.gov.sl).EVD(Ebola virus disease)BMI(body mass index)ENT(ear, nose and throat)FSFI(Female sexual function index)FSAD(Female sexual arousal disorder)IIEF(International index of erectile function)IQR(Interquartile range)AOR(Adjusted odds ratio)CI(Confidence interval)ETC(Ebola treatment Centre)